Literature DB >> 18395486

Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2.

Lynne A Murray1, Rochelle L Argentieri, Francis X Farrell, Michelle Bracht, Hai Sheng, Brian Whitaker, Heena Beck, Ping Tsui, Karyn Cochlin, Holly L Evanoff, Cory M Hogaboam, Anuk M Das.   

Abstract

One of the hallmarks of idiopathic pulmonary fibrosis with a usual interstitial pneumonia histological pathology (IPF/UIP) is excess collagen deposition, due to enhanced fibroblast extracellular matrix synthetic activity. Studies using murine models of lung fibrosis have elucidated a pro-fibrotic pathway involving IL-13 driving CCL2, which in turn drives TGFbeta1 in lung fibroblasts. Therefore, we sought to determine whether this pathway exists in the human fibrotic setting by evaluating human IPF/UIP fibroblasts. IPF/UIP fibroblasts have an increased baseline fibrotic phenotype compared to non-fibrotic fibroblasts. Interestingly, non-fibrotic fibroblasts responded in a pro-fibrotic manner to TGFbeta1 but were relatively non-responsive to IL-13 or CCL2, whereas, IPF/UIP cells were hyper-responsive to TGFbeta1, IL-13 and CCL2. Interestingly, TGFbeta1, CCL2 and IL-13 all upregulated TGFbeta receptor and IL-13 receptor expression, suggesting an ability of the mediators to modulate the function of each other. Furthermore, in vivo, neutralization of both JE and MCP5, the two functional orthologs of CCL2, during bleomycin-induced pulmonary fibrosis significantly reduced collagen deposition as well as JE and CCR2 expression. Also in the bleomycin model, CTGF, which is highly induced following TGFbeta stimulation, was attenuated with anti-JE/anti-MCP5 treatment. Overall this study demonstrates an interplay between TGFbeta1, IL-13 and CCL2 in IPF/UIP, where these three mediators feedback on each other, promoting the fibrotic response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395486     DOI: 10.1016/j.biocel.2008.02.016

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  64 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Modulation of lung inflammation by the Epstein-Barr virus protein Zta.

Authors:  James F Guenther; Jennifer E Cameron; Hong T Nguyen; Yu Wang; Deborah E Sullivan; Bin Shan; Joseph A Lasky; Erik K Flemington; Gilbert F Morris
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

Review 3.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 4.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

Review 5.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Authors:  Thomas A Wynn; Thirumalai R Ramalingam
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

6.  Negative regulation of lung inflammation and immunopathology by TNF-α during acute influenza infection.

Authors:  Daniela Damjanovic; Maziar Divangahi; Kapilan Kugathasan; Cherrie-Lee Small; Anna Zganiacz; Earl G Brown; Cory M Hogaboam; Jack Gauldie; Zhou Xing
Journal:  Am J Pathol       Date:  2011-10-14       Impact factor: 4.307

7.  Oxidative damage and TGF-β differentially induce lung epithelial cell sonic hedgehog and tenascin-C expression: implications for the regulation of lung remodelling in idiopathic interstitial lung disease.

Authors:  Paul M Fitch; Sarah E M Howie; William A H Wallace
Journal:  Int J Exp Pathol       Date:  2010-10-29       Impact factor: 1.925

8.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

Review 9.  Host responses in tissue repair and fibrosis.

Authors:  Jeremy S Duffield; Mark Lupher; Victor J Thannickal; Thomas A Wynn
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

10.  Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Authors:  Olga B Garbuzenko; Vera Ivanova; Vladislav Kholodovych; David C Reimer; Kenneth R Reuhl; Edvard Yurkow; Derek Adler; Tamara Minko
Journal:  Nanomedicine       Date:  2017-04-19       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.